How have KIDS shares performed this year?

OrthoPediatrics' stock was trading at $32.51 at the beginning of 2024. Since then, KIDS stock has decreased by 5.2% and is now trading at $30.81. View the best growth stocks for 2024 here .

How were OrthoPediatrics' earnings last quarter?

OrthoPediatrics Corp. (NASDAQ:KIDS) posted its quarterly earnings data on Monday, May, 6th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.12. The business earned $44.69 million during the quarter, compared to analyst estimates of $41.63 million. OrthoPediatrics had a negative trailing twelve-month return on equity of 5.12% and a negative net margin of 13.58%.

What is Mark Throdahl's approval rating as OrthoPediatrics' CEO?

15 employees have rated OrthoPediatrics Chief Executive Officer Mark Throdahl on Glassdoor.com . Mark Throdahl has an approval rating of 100% among the company's employees. This puts Mark Throdahl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did OrthoPediatrics IPO?

OrthoPediatrics (KIDS) raised $52 million in an initial public offering on Thursday, October 12th 2017. The company issued 4,000,000 shares at $12.00-$14.00 per share. Piper and Jaffray Stifel acted as the underwriters for the IPO and William Blair and BTIG were co-managers.

How do I buy shares of OrthoPediatrics?

Shares of KIDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

What other stocks do shareholders of OrthoPediatrics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OrthoPediatrics investors own include AbbVie (ABBV) , Freeport-McMoRan (FCX) , Gilead Sciences (GILD) , Intel (INTC) , Advanced Micro Devices (AMD) , CRISPR Therapeutics (CRSP) and Cisco Systems (CSCO) .

Positive News SentimentPositive News

NASDAQ:KIDS

OrthoPediatrics (KIDS) Stock Price, News & Analysis

$30.81

+0.87 (+2.91%)

(As of 07/5/2024 ET)

Compare

Today's Range: $29.42
▼
$30.88
50-Day Range: $27.75
▼
$34.70
52-Week Range: $23.10
▼
$45.96

Volume: 80,657 shs
Average Volume: 124,710 shs
Market Capitalization: $734.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $45.50

Get OrthoPediatrics alerts:

OrthoPediatrics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 47.7% Upside
$45.50 Price Target
Short Interest: Healthy
6.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.20
Upright™ Environmental Score
News Sentiment: 1.57
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.20) to ($1.32) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.14 out of 5 stars

Medical Sector

147th out of 879 stocks

Surgical & Medical Instruments Industry

23rd out of 95 stocks

3.4

Analyst's Opinion

Consensus Rating
OrthoPediatrics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
OrthoPediatrics has only been the subject of 3 research reports in the past 90 days.
Read more about OrthoPediatrics' stock forecast and price target.

3.0

Short Interest

Percentage of Shares Shorted
6.52% of the float of OrthoPediatrics has been sold short.
Short Interest Ratio / Days to Cover
OrthoPediatrics has a short interest ratio ("days to cover") of 7.2.
Change versus previous month
Short interest in OrthoPediatrics has recently decreased by 5.45%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
OrthoPediatrics does not currently pay a dividend.
Dividend Growth
OrthoPediatrics does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
OrthoPediatrics has received a 52.35% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic bone grafts", "Cervical implants", and "Medical screws" products. See details.
Environmental Sustainability
The Environmental Impact score for OrthoPediatrics is -1.20.

3.1

News and Social Media Coverage

News Sentiment
OrthoPediatrics has a news sentiment score of 1.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for OrthoPediatrics this week, compared to 2 articles on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OrthoPediatrics insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.80% of the stock of OrthoPediatrics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
69.05% of the stock of OrthoPediatrics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about OrthoPediatrics' insider trading history.

0.0

Earnings and Valuation

Earnings Growth
Earnings for OrthoPediatrics are expected to decrease in the coming year, from ($1.20) to ($1.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OrthoPediatrics is -32.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OrthoPediatrics is -32.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OrthoPediatrics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
Read more about OrthoPediatrics' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”

Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.

Click here to see it because it’s a SHOCKER…

About OrthoPediatrics Stock (NASDAQ:KIDS)

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

KIDS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KIDS Stock News Headlines

July 4 at 2:44 AM | americanbankingnews.com

Short Interest in OrthoPediatrics Corp. (NASDAQ:KIDS) Decreases By 5.5%

June 4, 2024 | globenewswire.com

OrthoPediatrics Corp. to Participate in the Truist Securities MedTech Conference

July 7, 2024 | Stansberry Research (Ad)

BUY ALERT: Tiny tech play partners with US government

The Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).

May 15, 2024 | globenewswire.com

OrthoPediatrics Corp. Continued Leading Sponsorship at 2024 EPOSNA Annual Meeting

May 8, 2024 | finance.yahoo.com

OrthoPediatrics Corp. (NASDAQ:KIDS) Q1 2024 Earnings Call Transcript

May 8, 2024 | finance.yahoo.com

OrthoPediatrics Corp (KIDS) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth and ...

May 8, 2024 | finance.yahoo.com

OrthoPediatrics First Quarter 2024 Earnings: Beats Expectations

May 7, 2024 | markets.businessinsider.com

Expert Ratings For OrthoPediatrics

July 7, 2024 | Stansberry Research (Ad)

BUY ALERT: Tiny tech play partners with US government

May 7, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Enanta Pharmaceuticals (ENTA), OrthoPediatrics (KIDS) and Avanos Medical (AVNS)

May 7, 2024 | finance.yahoo.com

OrthoPediatrics: Q1 Earnings Snapshot

May 7, 2024 | msn.com

KIDS Stock Earnings: OrthoPediatrics Beats EPS, Beats Revenue for Q1 2024

May 6, 2024 | finance.yahoo.com

OrthoPediatrics Corp (KIDS) Q1 2024 Earnings: Revenue Surges, Outperforming Analyst Forecasts

May 6, 2024 | globenewswire.com

OrthoPediatrics Corp. Reports First Quarter 2024 Financial Results and Increases Full Year 2024 Revenue Guidance

May 5, 2024 | markets.businessinsider.com

Strong Buy Rating for OrthoPediatrics: Sustained Growth and Market Expansion Fuel Optimism

May 2, 2024 | finance.yahoo.com

OrthoPediatrics Corp. Receives “Breakthrough Device” Designation from FDA for eLLi™ Growing Rod System for Pediatric Patients with Scoliosis

April 22, 2024 | globenewswire.com

OrthoPediatrics Corp. to Report First Quarter 2024 Financial Results on May 7, 2024

April 10, 2024 | markets.businessinsider.com

The Analyst Verdict: OrthoPediatrics In The Eyes Of 6 Experts

See More Headlines

Receive KIDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OrthoPediatrics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/06/2024
Today: 7/07/2024
Next Earnings (Estimated): 7/29/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:KIDS
CUSIP: N/A
CIK: 1425450
Web: www.orthopediatrics.com
Phone: (574) 268-6379
Fax: 574-269-3692
Employees: 247
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $45.50
High Stock Price Target: $52.00
Low Stock Price Target: $38.00
Potential Upside/Downside: +47.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,970,000.00
Net Margins: -13.58%
Pretax Margin: -15.00%
Return on Equity: -5.12%
Return on Assets: -4.41%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 4.45
Quick Ratio: 1.99

Sales & Book Value

Annual Sales: $148.73 million
Price / Sales: 4.94
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $16.14 per share
Price / Book: 1.91

Miscellaneous

Outstanding Shares: 23,830,000
Free Float: 16,251,000
Market Cap: $734.20 million
Optionable: Optionable
Beta: 1.19

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Mark C. Throdahl (Age 73)
Executive Chairman
Mr. David R. Bailey (Age 45)
President, CEO & Director
Comp: $588.47k
Mr. Fred L. Hite (Age 56)
CFO, Principal Financial & Accounting Officer, COO and Director
Comp: $578.75k
Mr. Daniel J. Gerritzen (Age 54)
Executive VP of Legal & General Counsel
Comp: $470.44k
Mr. Gregory A. Odle (Age 54)
President of Scoliosis
Comp: $484.32k
Mr. Kevin L. Unger CHE (Age 52)
MBA/MSHA, President of Enabling Technologies
Comp: $56.25k
Mr. Joseph W. Hauser (Age 42)
President of Trauma & Deformity Correction
Comp: $470.44k
Mr. Joel Batts
Senior Vice President of Clinical & Regulatory Affairs
Mr. Mark Karshner
Senior Vice President of International Sales

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KIDS Stock Analysis - Frequently Asked Questions

How have KIDS shares performed this year?: OrthoPediatrics' stock was trading at $32.51 at the beginning of 2024. Since then, KIDS stock has decreased by 5.2% and is now trading at $30.81.
View the best growth stocks for 2024 here.
How were OrthoPediatrics' earnings last quarter?: OrthoPediatrics Corp. (NASDAQ:KIDS) posted its quarterly earnings data on Monday, May, 6th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.12. The business earned $44.69 million during the quarter, compared to analyst estimates of $41.63 million. OrthoPediatrics had a negative trailing twelve-month return on equity of 5.12% and a negative net margin of 13.58%.
What is Mark Throdahl's approval rating as OrthoPediatrics' CEO?: 15 employees have rated OrthoPediatrics Chief Executive Officer Mark Throdahl on Glassdoor.com. Mark Throdahl has an approval rating of 100% among the company's employees. This puts Mark Throdahl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
When did OrthoPediatrics IPO?: OrthoPediatrics (KIDS) raised $52 million in an initial public offering on Thursday, October 12th 2017. The company issued 4,000,000 shares at $12.00-$14.00 per share. Piper and Jaffray Stifel acted as the underwriters for the IPO and William Blair and BTIG were co-managers.
How do I buy shares of OrthoPediatrics?: Shares of KIDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
What other stocks do shareholders of OrthoPediatrics own?: Based on aggregate information from My MarketBeat watchlists, some other companies that OrthoPediatrics investors own include AbbVie (ABBV), Freeport-McMoRan (FCX), Gilead Sciences (GILD), Intel (INTC), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP) and Cisco Systems (CSCO).